Tenax Therapeutics Inc logo

Tenax Therapeutics Inc

NAS:TENX (USA)  
$ 4.24 +0.37 (+9.56%) 11:09 PM EST
At Loss
P/B:
0.11
Enterprise V:
$ -3.48M
Volume:
205.97K
Avg Vol (2M):
497.10K
Also Trade In:
Volume:
205.97K
At Loss
Avg Vol (2M):
497.10K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for TENX ( Tenax Therapeutics Inc ) from 1997 to Mar 30 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Tenax Therapeutics stock (TENX) PE ratio as of Mar 30 2024 is 0. More Details

Tenax Therapeutics Inc (TENX) PE Ratio (TTM) Chart

To

Tenax Therapeutics Inc (TENX) PE Ratio (TTM) Historical Data

Total 1201
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Tenax Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-30 At Loss 2024-01-29 At Loss
2024-03-29 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss
2024-03-12 At Loss 2024-01-09 At Loss
2024-03-11 At Loss 2024-01-08 At Loss
2024-03-08 At Loss 2024-01-05 At Loss
2024-03-07 At Loss 2024-01-04 At Loss
2024-03-06 At Loss 2024-01-03 At Loss
2024-03-05 At Loss 2024-01-02 At Loss
2024-03-04 At Loss 2024-01-01 At Loss
2024-03-01 At Loss 2023-12-29 At Loss
2024-02-29 At Loss 2023-12-28 At Loss
2024-02-28 At Loss 2023-12-27 At Loss
2024-02-27 At Loss 2023-12-26 At Loss
2024-02-26 At Loss 2023-12-22 At Loss
2024-02-23 At Loss 2023-12-21 At Loss
2024-02-22 At Loss 2023-12-20 At Loss
2024-02-21 At Loss 2023-12-19 At Loss
2024-02-20 At Loss 2023-12-18 At Loss
2024-02-19 At Loss 2023-12-15 At Loss
2024-02-16 At Loss 2023-12-14 At Loss
2024-02-15 At Loss 2023-12-13 At Loss
2024-02-14 At Loss 2023-12-12 At Loss
2024-02-13 At Loss 2023-12-11 At Loss
2024-02-12 At Loss 2023-12-08 At Loss
2024-02-09 At Loss 2023-12-07 At Loss
2024-02-08 At Loss 2023-12-06 At Loss
2024-02-07 At Loss 2023-12-05 At Loss
2024-02-06 At Loss 2023-12-04 At Loss
2024-02-05 At Loss 2023-12-01 At Loss
2024-02-02 At Loss 2023-11-30 At Loss
2024-02-01 At Loss 2023-11-29 At Loss
2024-01-31 At Loss 2023-11-28 At Loss
2024-01-30 At Loss 2023-11-27 At Loss

Tenax Therapeutics Inc (TENX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.